Monoclonal gammopathy of undetermined significance laboratory findings

Revision as of 13:57, 14 August 2018 by Okamal (talk | contribs) (→‎Overview)
Jump to navigation Jump to search

Monoclonal gammopathy of undetermined significance Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Monoclonal gammopathy of undetermined significance from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Monoclonal gammopathy of undetermined significance laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Monoclonal gammopathy of undetermined significance laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Monoclonal gammopathy of undetermined significance laboratory findings

on Monoclonal gammopathy of undetermined significance laboratory findings

Monoclonal gammopathy of undetermined significance laboratory findings in the news

Blogs on Monoclonal gammopathy of undetermined significance laboratory findings

Directions to Hospitals Treating Monoclonal gammopathy of undetermined significance

Risk calculators and risk factors for Monoclonal gammopathy of undetermined significance laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Omer Kamal, M.D.[2]

Overview

Patients may be diagnosed with MGUS if they fulfill the three component criteria which includes a monoclonal paraprotein band less than 3 g/dl, plasma cells less than 10% on bone marrow examination, and no evidence of bone lesions, anemia, hypercalcemia, or renal insufficiency related to the paraprotein. Check the blood for hypercalcemia and deterioration in renal function, check the urine for Bence-Jones protein.

Laboratory Findings

Patients may be diagnosed with MGUS if they fulfill the following three criteria:[1]

  1. A monoclonal paraprotein band less than 3 g/dl;
  2. Plasma cells less than 10% on bone marrow examination; and
  3. No evidence of bone lesions, anemia, hypercalcemia, or renal insufficiency related to the paraprotein.

Check the blood for hypercalcemia and deterioration in renal function, check the urine for Bence-Jones protein

References

  1. International Myeloma Working Group (2003). "Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group". Br J Haematol. 121 (5): 749–57. PMID 12780789.

Template:WH Template:WS